Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.

A solid tumor forms an organ-like entity comprised of neoplastic cells and non-transformed host stromal cells embedded in an extracellular matrix. Similar to normal tissues, blood vessels nourish cells residing in tumors. However, unlike normal blood vessels, tumor vasculature has abnormal organization, structure, and function. Tumor vessels are leaky and blood flow is heterogeneous and often compromised. Vascular hyperpermeability and the lack of functional lymphatic vessels inside tumors cause elevation of interstitial fluid pressure in solid tumors. Each of these abnormalities forms a physiological barrier to the delivery of therapeutic agents to tumors. Furthermore, elevated tumor interstitial fluid pressure increases fluid flow from the tumor margin into the peri-tumor area and may facilitate peri-tumor lymphatic hyperplasia and metastasis. Abnormal microcirculation in tumors also leads to a hostile microenvironment characterized by hypoxia and acidosis, which hinder the effectiveness of anti-tumor treatments such as radiation therapy and chemotherapy. In addition, host-tumor interactions regulate expression of pro- and anti-angiogenic factors and hence contribute to their imbalance and resulting pathophysiological characteristics of the tumor. Restoration of pro- and anti-angiogenic balance in tumors may "normalize" tumor vasculature and thus improve its function. Indeed, anti-angiogenic treatments directly targeting angiogenic signaling pathways as well as indirectly modulating angiogenesis show normalization of tumor vasculature and microenvironment at least transiently in both preclinical and clinical settings. Combination of cytotoxic therapy and anti-angiogenic treatment during the vascular normalization exhibits synergistic effect.

[1]  E. Rofstad,et al.  Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. , 2006, Cancer research.

[2]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[3]  P. Abrams,et al.  Radioimmunotherapy of Cancer , 2000 .

[4]  S. Larson,et al.  “Artificial Lymphatic System”: A New Approach to Reduce Interstitial Hypertension and Increase Blood Flow, pH and pO2 in Solid Tumors , 2000, Annals of Biomedical Engineering.

[5]  R. Weinberg,et al.  Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. , 2001, Experimental cell research.

[6]  M. Dewhirst,et al.  Concepts of oxygen transport at the microcirculatory level. , 1998, Seminars in radiation oncology.

[7]  Marc Dellian,et al.  Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[9]  R. Jain,et al.  Delivery of Molecular and Cellular Medicine to Solid Tumors , 1997, Advanced drug delivery reviews.

[10]  R. Jain,et al.  Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  G. Semenza Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[12]  R K Jain,et al.  Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors. , 2000, Cancer research.

[13]  R. Jain,et al.  NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels. , 2005, The Journal of clinical investigation.

[14]  C. Berking,et al.  Function and regulation of melanoma–stromal fibroblast interactions: when seeds meet soil , 2003, Oncogene.

[15]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[16]  Rakesh K Jain,et al.  Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics , 2002, Science.

[17]  R. Jain,et al.  Acidic Extracellular pH Induces Vascular Endothelial Growth Factor (VEGF) in Human Glioblastoma Cells via ERK1/2 MAPK Signaling Pathway , 2002, The Journal of Biological Chemistry.

[18]  R. Jain,et al.  Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. , 1994, Cancer research.

[19]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[20]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[21]  R K Jain,et al.  Quantitation and physiological characterization of angiogenic vessels in mice: effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. , 1996, The American journal of pathology.

[22]  R K Jain,et al.  Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  R K Jain,et al.  Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. , 1997, The American journal of pathology.

[24]  R. Jain,et al.  Microvascular permeability of normal and neoplastic tissues. , 1986, Microvascular research.

[25]  C. Compton,et al.  Tumor–host interactions in the gallbladder suppress distal angiogenesis and tumor growth: Involvement of transforming growth factor β1 , 1999, Nature Medicine.

[26]  R. Jain,et al.  Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. , 2000, Cancer research.

[27]  R. Jain,et al.  Solid stress generated by spheroid growth estimated using a linear poroelasticity model. , 2003, Microvascular research.

[28]  Rakesh K Jain,et al.  A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood , 2007, Nature Protocols.

[29]  Elise C. Kohn,et al.  The microenvironment of the tumour–host interface , 2001, Nature.

[30]  R. Jain,et al.  Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. , 2001, Cancer research.

[31]  N. Fusenig,et al.  Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. , 2005, Cancer research.

[32]  Rakesh K. Jain,et al.  Pathology: Cancer cells compress intratumour vessels , 2004, Nature.

[33]  Rakesh K Jain,et al.  Mosaic tumor vessels: cellular basis and ultrastructure of focal regions lacking endothelial cell markers. , 2005, Cancer research.

[34]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[35]  P. C. Johnson Landis Award Lecture. The myogenic response and the microcirculation. , 1977, Microvascular research.

[36]  Gary G. Meadows,et al.  Integration/Interaction of Oncologic Growth , 2005 .

[37]  Lei Xu,et al.  Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.

[38]  Melody A. Swartz,et al.  Interstitial Flow as a Guide for Lymphangiogenesis , 2003, Circulation research.

[39]  I. Tannock,et al.  Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. , 1997, British Journal of Cancer.

[40]  T. Tlsty,et al.  Stromal cells can contribute oncogenic signals. , 2001, Seminars in cancer biology.

[41]  R. Jain Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[42]  S. Heiland,et al.  Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. , 2005, Cancer research.

[43]  Zvi Fuks,et al.  Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis , 2003, Science.

[44]  R K Jain,et al.  Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. , 1992, Cancer research.

[45]  R K Jain,et al.  Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. , 1994, Cancer research.

[46]  R K Jain,et al.  Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Janice M. Y. Brown,et al.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.

[48]  Dai Fukumura,et al.  Peritumor Lymphatics Induced by Vascular Endothelial Growth Factor-C Exhibit Abnormal Function , 2004, Cancer Research.

[49]  Lei Xu,et al.  Pancreas Microenvironment Promotes VEGF Expression and Tumor Growth: Novel Window Models for Pancreatic Tumor Angiogenesis and Microcirculation , 2001, Laboratory Investigation.

[50]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.

[51]  R K Jain,et al.  Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. , 1999, Cancer research.

[52]  Dennis C. Sgroi,et al.  Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.

[53]  R K Jain,et al.  Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. , 2001, Cancer research.

[54]  Dai Fukumura,et al.  Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize , 2007, Journal of cellular biochemistry.

[55]  M Ancukiewicz,et al.  Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. , 2000, Cancer research.

[56]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[57]  V. Grégoire,et al.  Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  I. Fidler,et al.  Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. , 2001, Journal of the National Cancer Institute.

[59]  D. Ruiter,et al.  Tumour metastasis: is tissue an issue? , 2001, The Lancet. Oncology.

[60]  Dai Fukumura,et al.  Dissecting tumour pathophysiology using intravital microscopy , 2002, Nature Reviews Cancer.

[61]  R. Xavier,et al.  Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.

[62]  Dai Fukumura,et al.  Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. , 2006, Cancer research.

[63]  Ricky T. Tong,et al.  Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. , 2007, Cancer research.

[64]  R. Skalak,et al.  Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. , 1995, Cancer research.

[65]  B Landuyt,et al.  Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 , 2003, British Journal of Cancer.

[66]  J. Pollard Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[67]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[68]  M Intaglietta,et al.  Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[69]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[70]  R K Jain,et al.  Fluorescence ratio imaging measurement of pH gradients: calibration and application in normal and tumor tissues. , 1993, Microvascular research.

[71]  Lei Xu,et al.  Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. , 2006, Cancer research.

[72]  C. Bucana,et al.  Regulation of interleukin-8 expression in human melanoma cells by the organ environment. , 1995, Cancer research.

[73]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[74]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[75]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[76]  Robert S. Kerbel,et al.  The anti-angiogenic basis of metronomic chemotherapy , 2004, Nature Reviews Cancer.

[77]  James L Tatum,et al.  Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy , 2006, International journal of radiation biology.

[78]  R. Jain,et al.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.

[79]  R K Jain,et al.  Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[80]  Ricky T. Tong,et al.  Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  R K Jain,et al.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.

[82]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[83]  C. Bucana,et al.  Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. , 1994, The American journal of pathology.

[84]  D. Fukumura,et al.  Hypoxia-Induced Activation of p38 Mitogen-Activated Protein Kinase and Phosphatidylinositol 3′-Kinase Signaling Pathways Contributes to Expression of Interleukin 8 in Human Ovarian Carcinoma Cells , 2004, Clinical Cancer Research.

[85]  Tatiana V. Petrova,et al.  Lymphangiogenesis in development and human disease , 2005, Nature.

[86]  Rakesh K. Jain,et al.  Transport of molecules across tumor vasculature , 2004, Cancer and Metastasis Reviews.

[87]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[88]  J. Foidart,et al.  Enhancement of tumorigenicity of human breast adenocarcinoma cells in nude mice by matrigel and fibroblasts. , 1993, British Journal of Cancer.

[89]  P. Choyke,et al.  Imaging of angiogenesis: from microscope to clinic , 2003, Nature Medicine.

[90]  R. Weinberg,et al.  The Biology of Cancer , 2006 .

[91]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[92]  R. Weinberg,et al.  Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. , 2007, Cancer research.